Naoto T Ueno, MD, PhD@teamoncology
Subcutaneous vs IV Herceptin for Patients With HER2+ Early Breast Cancer: Final Analysis of Phase 3 Randomized Clinical Trial. Same efficacy & safety. How much can we save financially by SC? At least, we can get rid of CVC for those who need monoRx. #bcsm https://jamanetwork.com/journals/jamaoncology/fullarticle/2730632…
posted at 16:05:52